Intriguingly, several studies aimed to explore whether sivelestat sodium, a type of NE inhibitor, could attenuate the postoperative complications of esophageal cancer patients; and these studies found that sivelestat sodium could significantly lighten postoperative hypoxia, partially reduce systemic inflammation, and maintain postoperative circulatory status, which is beneficial for the recovery of patients (126–128). This evidence concerns the gene ELANE and esophageal cancer.